

# SCHOTT PHARMA strengthens its leading position

**S**chott Pharma is celebrating its first anniversary as a legally-attested, stand-alone company in the field of pharma drug containment solutions and delivery systems. The former pharma division of the Schott Group has continued its profitable growth trajectory by supplying high-value solutions that enable pharma manufacturers to safely store and deliver life-saving drugs. In its first year as a carved-out entity, Schott Pharma has further enhanced its line of products, offering the broadest portfolio in the market while catering to the most important trends in the industry: “From new drug categories that require deep-cold storage and more efficient production set-ups to a shift from hospital to homecare treatments, Pharma companies around the world continue to trust Schott Pharma to provide the ideal solution,” said Andreas Risse, CEO of Schott Pharma. On average, more than 25,000 injections per minute are provided to patients worldwide through a Schott Pharma product.

Here the company builds upon a global entrepreneurial success story rooted in both innovation and a hundred years of manufacturing expertise. With a strong global R&D team coupled with close collaboration with an exclusive network of customers and partners, Schott Pharma is setting new industry standards through



With its high-value solutions, SCHOTT PHARMA celebrates one year as a standalone company that offers a broad portfolio catering to various industry trends. A global market leader, it operates 16 production sites and supplies over 1,800 customers worldwide – a noteworthy footprint which has already yielded a 13.2 percent YoY growth, with sales reaching EUR 449 million in H1 2023.

innovation. “We continue to stay ahead by following a holistic, systemic approach that’s based on science and puts patients’ needs first,” explains Reisse.

#### ORIENTED TO THE FUTURE

This forward-looking mindset has led to recent developments, which include:

- The latest Schott TOPPAC® freeze innovation, which allows pharma companies to market their deep-cold medications directly in prefilled polymer syringes for the first time.
- The development of ready-to-use solutions, where Schott Pharma delivers pre-washed and sterilized products to reduce the supply chain complexities for pharma companies.


- Allowing patients to administer drugs in the comfort of their home by providing fully integrated homecare systems together with device manufacturers - which helps reduce healthcare costs.

#### HIGH-VALUE SOLUTIONS – A KEY DRIVER OF PROFITABILITY

As recently reported, the company’s strategy of delivering high-value solutions that cater to long-term trends in the pharma industry continues to be a key driver of profitability. Over the first half of the fiscal year 2023 the company generated sales of EUR 449 million, marking a strong 13.2 percent year-on-year growth. EBITDA increased by

16.6 percent to EUR 132 million, resulting in an EBITDA margin of 29.4 percent which was one full percentage point higher than the same period in 2022. “Our strategy of focusing on high-value solutions is paying off as the share of sales from high-margin, high-value solutions increased significantly to 45 percent,” said Almuth Steinkühler, CFO of Schott Pharma.

As a global market leader with a pure-play focus on injectables, Schott Pharma is represented in all major pharma hubs with 16 state-of-the-art production sites in Europe, North and Latin America, as well as Asia. The company produces around 13 billion prefilled glass and polymer syringes, cartridges, vials and ampoules each year. By supplying over 1,800 customers, Schott Pharma is helping to make breakthrough therapies available to patients around the world. ■



**SCHOTT  
PHARMA**

**SCHOTT PHARMA  
AG & CO.  
KGAA**

Hattenbergstraße 10  
55118 Mainz – GERMANY  
Tel.: +49-6131-660  
E-mail: [pharma@schott.com](mailto:pharma@schott.com)  
[www.schott-pharma.com](http://www.schott-pharma.com)